REX Health Ventures is a venture capital firm that invests in healthcare companies.

REX Health Ventures

MedTech World is a global event management company that organizes an annual investor and entrepreneur conference in the medtech and health tech sector in Malta, along with multiple roadshow events worldwide. It fosters collaboration among stakeholders to enhance healthcare.

MedTech World

Rex Health Ventures (RHV) enables groundbreaking work by investing in and fostering companies and technologies that advance the future of health. As an entrepreneur-friendly strategic investor, RHV accelerates access to new healthcare products and services to improve patient care. RHV was established by UNC REX in 2012 as part of its commitment to innovation. Leveraging the talent and subject matter experts across UNC REX and the UNC Health network, RHV partners with emerging companies throughout North Carolina and the U.S.

Bardy Diagnostics

Veran Medical Technologies

Gauss Surgical

Phynd Technologies

Rex Health Ventures

Wonderful to see Censinet's recent release of the CPG Compliance Starter Toolkit, now available for American Hospital Association members.

This toolkit is like the Swiss Army knife of compliance towards the recently-announced goals – loaded with great tools to assess, align, benchmark, implement, monitor, and comply with Essential and Enhanced CPGs.

Grateful to the American Hospital Association for the collaboration and to Ed Gaudet and the Censinet team for all their effort in making this initiative happen. Thanks for all you do to continue making our healthcare ecosystem safer from cyberthreats.

Evan Bernath, Anita Watkins, John Perez, Rex Health Ventures

#HealthcareInnovation #Cybersecurity #Compliance

Big news from Arrivo BioVentures LLC! 
 
The FDA has granted Fast Track Designation to their novel lipase inhibitor, RABI-767, for the treatment of patients with acute pancreatitis at risk of progressing to severe disease.
 
“The Fast Track Designation highlights the high unmet medical need for patients with acute pancreatitis and the importance of finding safe, effective treatments,” said Steve Butts, CEO of Arrivo BioVentures.
 
Congratulations to Steve Butts and the entire Arrivo BioVentures team for this significant milestone. Rex Health Ventures is proud to support their innovative efforts in bringing life-saving solutions to patients facing this critical disease.
 
Anita Watkins, Evan Bernath, Natasha Bonett DeLong, John Perez, UNC Health
 
#Innovation #RexHealthVentures #FDAFastTrackDesignation #AcutePancreatitis #UNCHealth #CVC

Thank you for the great conversation with Giovanni Lauricella!  Rex Health Ventures, UNC Health, UNC Health Rex, MedTech World

We are thrilled to share the latest episode of the MedTech Startup Podcast featuring our very own Anita Watkins, Managing Director at Rex Health Ventures!
 
Anita sat down with Giovanni Lauricella, Managing Partner of Lifeblood, in Malta at MedTech World to discuss the pivotal role of UNC Health and hospital venture arms in MedTech innovation. Tune in to hear Anita’s insights on:
 
- Investment strategies for MedTech startups
- The unique advantages of partnering with hospital venture arms
- Significance of clinical data and early advocates
 
Thanks, Giovanni Lauricella, for hosting a great discussion. Don’t miss this deep dive into the world of healthcare system venture investing and reach out if you’d like to get more deeply connected with the Rex Health Ventures team.
 
https://lnkd.in/gRDwFXuG
 
John Perez, Evan Bernath, Natasha Bonett DeLong
 
#MedTech #Innovation #VentureCapital #Healthcare #CVC #RexHealthVentures

Let’s keep the good news rolling – congrats to Vergent Bioscience for this great validation! 

The Annals Of Thoracic Surgery has published Phase 2 data demonstrating that Vergent Bioscience’s tumor-targeted imaging agent, VGT-309, may help surgeons visualize difficult-to-find and previously undetected tumors during minimally invasive and robotic-assisted surgeries. 

Rex Health Ventures is proud of John Santini and the entire Vergent Bioscience team for their relentless innovation and dedication to improving patient lives. 

Anita Watkins, Evan Bernath, John Perez, UNC Health

#Innovation #RexHealthVentures #TumorVisualization #LungCancer #RoboticSurgery #SurgicalAdvancements #UNCHealth #CVC

💡 Applications for GRO are now open! 💡 

GRO is a 12-week Incubator powered by CED. 

If selected, you will attend weekly classes led by subject matter experts and seasoned entrepreneurs, where you will learn how to build a scalable business. Your company will be assigned a coach and you will receive 1:1 support, collaborate, and receive feedback as you progress.
 
Apply here ▶  https://lnkd.in/g_83FgE8

#GRO #entrepreneurship #startups

Metric
Company Name	REX Health Ventures	MedTech World
Symbol
MSH ID	COM:REXHEALTHVENTURES	WORLD:MED-TECH
Market	PRIVATE	PRIVATE
Sector	Financial Services & Finance	Commercial & Professional Services
Industry	Venture Capital	Event Management
Country	US	MT
Stage
Employee Count	5
Website	rexhealthventures.com	med-tech.world
LinkedIn	rex-health-ventures	mtw-medtech-world
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	774
Web Traffic Growth	1.10
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

REXH

COM:REXHEALTHVENTURES

REX Health Ventures

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue